Amphista Therapeutics is the leading Europe-based targeted protein degradation (TPD) company.
Founded by Advent Life Sciences, Amphista is built on the groundbreaking science from the laboratory of Professor Alessio Ciulli, University of Dundee, a world leader in the field of targeted protein degradation.
Professor Alessio Ciulli
Amphista takes its name from the mythical two-headed serpent the Amphisbaena (also known as an Amphista). In ancient times, Amphisbaenae were said to possess many health-giving properties.